Table 2.

HRAS-mutant salivary cancer patients treated with tipifarnib

Subject	Age at Dx	Gender	Race	Date of initial Dx	Primary site	Histology	Initial Stage	ARa	HER2 statusb	Initial Tx	Completed Initial Tx	First recurrence	Prior Systemic Tx	Started tipifarnib	Starting dosec	Time on therapy (months)d	BOR	% Tumor changee
1	48	M	W	06/15/13	PAR	AcCC	IVA	−	0	S+R	04/15/14	09/23/14	ICI	10/25/18	600 mg	14.0+	PR	−31.4
2	75	M	W	05/12/17	PAR	CexPA	IVA	+	0	S+R	09/26/17	01/16/18	ADT	03/08/19	600 mg	1.0	PD	+15.6
3	61	M	W	05/21/15	PAR	SDC	IVC	+	1+	C	--	--	ADT	09/09/16	900 mg	1.0	PD	+6.7
4	69	M	W	12/03/10	PAR	MyoEpC	IV	−	0	S+R	02/28/11	11/22/13	Phase I	09/30/15	900 mg	13.0	SD	−27.5
5	34	M	A	08/23/11	PAR	MyoEpC	IV			S	10/11/11	01/14/14	CT	05/13/15	300 mg	1.0	PD	+20.6
6	58	M	B	09/26/14	PAR	Adeno	IV	+	0	S+CRT	01/16/15	--	Cisplatin	01/14/16	900 mg	3.0	SD	−14.1
7	65	M	W	03/07/14	PAR	SDC	IV			S+CRT	06/30/14	03/07/15	Cisplatin	10/15/15	900 mg	7.0	SD	+6.9
8	53	F	W	12/09/11	PAR	OncCA	IV			S+CRT	03/26/12	09/04/15	Cisplatin	01/21/16	900 mg	8.0	SD	+3.1
9	73	M	W	08/16/17	PNS	SGC	IV			C	--	--	CD	02/20/18	900 mg	10.0	SD	−16.9
10	38	M	A	06/03/10	PAR	SDC	IVA	+	2+	S+CRT	09/09/10	02/15/12	Alpelisib	06/18/19	600 mg	6.0+	UE	--
11	56	F	W	08/25/11	PAR	MyoEpC	I	+	1+	S+R	11/16/11	10/25/16	CT	05/08/18	900 mg	5.0	SD	−14.2
12	59	M	W	06/15/08	PAR	MyoEpC	II			S+R	08/15/08	05/15/15	ICI	02/14/19	600 mg	10.0+	SD	−10.3
13	50	M	W	05/27/16	PAR	MEC	IVA	+	2+	S+R	08/15/16	11/28/17	ADT	05/20/19	600 mg	2.0	PD	+21.1

^areported ‘+’ if greater than or equal to 1% expression by immunohistochemistry (IHC) was observed, blank spaces were not available for testing;

^bHER-2/neu status was defined by IHC using standard immune expression intensity scoring from 0 to 1–3+ (none had amplification), if available;

^creported milligram (mg) doses were dosed by mouth twice daily;

^da ‘+’ indicates that the patient remains on therapy at the date of analysis (1/6/20);

^eas determined by RECIST v1.1 with central review; Dx = diagnosis, AR = androgen receptor, Tx = treatment, BOR = best overall response per RECIST v1.1, PAR = parotid, PNS = paranasal sinuses, AcCC = acinic cell carcinoma, CexPA = carcinoma ex pleomorphic adenoma, SDC = salivary duct carcinoma, MyoEpC = myoepithelial-epithelial carcinoma, Adeno = adenocarcinoma, OncCA = oncocytic carcinoma, SGC = salivary gland cancer not otherwise specified, MEC = mucoepidermoid carcinoma, S = surgery, R = radiation, CRT = concurrent chemoradiation, ICI = immune checkpoint inhibitor, ADT = androgen deprivation therapy, CT = carboplatin/paclitaxel, CD = carboplatin/docetaxel, SD = stable disease, PD = progression of disease, UE = unevaluable.